Xencor, Inc Property, Plant and Equipment, Gross
Xencor, Inc (XNCR) had Property, Plant and Equipment, Gross of $105.81 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization
us-gaap:PropertyPlantAndEquipmentGross · last filed 2026-08-05
- 2026-06-30: Property, Plant and Equipment, Gross $105.81M.
- 2026-03-31: Property, Plant and Equipment, Gross $105.32M.
- 2025-12-31: Property, Plant and Equipment, Gross $104.78M.
- 2025-09-30: Property, Plant and Equipment, Gross $103.99M.
| Period end | Property, Plant and Equipment, Gross |
|---|---|
| 2026-06-30 | $105.81M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $105.32M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $104.78M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $103.99M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $103.81M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $103.42M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $101.98M 10-K · filed 2026-02-25 |
| 2023-12-31 | $102.35M 10-K · filed 2025-02-27 |
| 2022-12-31 | $87.47M 10-K/A · filed 2025-02-24 |
| 2021-12-31 | $51.07M 10-K · filed 2023-02-27 |
| 2020-12-31 | $38.71M 10-K · filed 2022-02-24 |
| 2019-12-31 | $28.41M 10-K · filed 2021-02-24 |
| 2018-12-31 | $21.24M 10-K · filed 2020-02-25 |
| 2017-12-31 | $15.04M 10-K · filed 2019-02-26 |
| 2016-12-31 | $10.65M 10-K · filed 2018-02-28 |
| 2015-12-31 | $9.19M 10-K · filed 2017-03-01 |
| 2014-12-31 | $7.45M 10-K · filed 2016-03-08 |
| 2013-12-31 | $6.68M 10-K · filed 2015-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |